Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
AUSTIN, Texas, Sept. 01, 2016 -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare disease and cancer, today announced that its chief executive officer, David G. Lowe, Ph.D., will present at the 2016 Wells Fargo Healthcare Conference in Boston on Wednesday, September 7 at 1:45 p.m. EDT.
The presentation will be webcast and will be available for 90 days following the live presentation. The webcast can be viewed here and on the investor relations section of the Aeglea BioTherapeutics website.
About Aeglea BioTherapeutics
Aeglea is a biotechnology company committed to developing recombinant human enzymes for the treatment of rare diseases and cancers associated with abnormal amino acid metabolism. The company’s recombinant human enzymes are designed to degrade specific amino acids in the blood in order to reduce toxic levels of amino acids in rare diseases or to starve tumors dependent on amino acids by reducing levels below the normal range. Aeglea’s clinical program for its lead product candidate, AEB1102, includes three recently initiated Phase 1 clinical trials, studying AEB1102 for the treatment of patients with Arginase I deficiency as well as patients with solid tumors or hematological malignancies. The company is building a pipeline of additional product candidates targeting key amino acids, including AEB4104, which degrades homocystine, a target for an inborn error of metabolism, as well as two potential treatments for cancer, AEB3103, which degrades cysteine/cystine, and AEB2109, which degrades methionine.
For more information, visit http://aegleabio.com.
Media Contact: Kelly Boothe, Ph.D. BrewLife 415.946.1076 [email protected] Investor Contact: Charles N. York II Chief Financial Officer Aeglea BioTherapeutics [email protected]
